drugset / Trial / NCT03885180

Randomized Evaluation of D-dimer Guiding dUration of Oral antiCoagulation thErapy

NCT03885180

Unknown 500 enrolled Wuhan Asia Heart Hospital
RandomizedParallel-groupOpen-labelPrevention

Summary

Guidelines recommended that patients with bioprosthetic heart valves (BHV) only need 6 months oral anticoagulation therapy after operation. However, a small part of patients still suffered thrombotic events after withdrawal of warfarin, which means these patients may need extend anticoagulation therapy. D-dimer, a sensitive marker of thrombosis or prethromboembolism state. Previous studies have demostrated that patients with elevated D-dimer levels have significant more clinical outcomes than those with nagative D-dimer levels. The aim of this study was to evaluate whether D-dimer could guide the duration of oral anticoagulation therapy in patients with BHV.

Timeline

Start
2019-03-20
Primary completion
2021-03-01
Completion
2021-03-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Warfarin Small molecule Oral